Danirixin

Danirixin is a small molecule, non-peptide, high affinity (IC50 for CXCL8 binding = 12.5 nM), selective, and reversible CXCR2 antagonist. 

Danirixin is a small molecule CXCR2 antagonist being evaluated as a potential anti-inflammatory medicine. Danirixin has demonstrated potent antagonism of CXCR2 activity in vitro and anti-inflammatory effects in various preclinical models. Its pharmacologic activity and duration of action following oral administration support its potential use as an oral, anti-inflammatory agent. Danirixin (GSK1325756) is a small, high-affinity, selective and reversible CXCR2 antagonist in development for treatment of chronic obstructive pulmonary disease. Danirixin (GSK1325756) is a small, non-peptide, high-affinity (IC50 for CXCL8 binding 12.5 nM), selective and reversible CXCR2 antagonist. Danirixin has demonstrated potent antagonism of CXCR2 activity, both in vitro and in vivo in preclinical studies. Its oral potency and duration of action support its potential use as an oral, anti-inflammatory agent in the treatment of disorders associated with the accumulation of neutrophils.